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Uniquely among modern heroin prescribing trials, the trial in Germany was not confined 
to heroin-addicted patients who had done poorly on methadone, offering the opportunity 
to assess whether heroin should be reserved for these patients. The conclusion was that 
other patients too benefit more from injectable heroin than oral methadone. 
Summary This account also draws on the main report from the trial of which the 
featured report was a sub-study. The study trialled the prescribing of heroin for the 
treatment of heroin addiction at seven German clinics. Over the years 2002 and 2003 it 
successfully recruited 1015 patients who were continuing to regularly inject heroin and 
were in poor physical or mental health despite currently being in methadone maintenance 
treatment, or having been treated for their addiction in the past but not in the last six 
months. Uniquely among modern trials, because the past treatment need not have been 
opiate substitute prescribing, the trial was not confined to patients who had previously 
done poorly on methadone, offering the opportunity taken by the featured report to 
assess whether heroin prescribing should be reserved to these patients.
Patients were randomly allocated to either be prescribed heroin to be taken under 
supervision at the clinics plus oral methadone, or only oral methadone. Cutting across 
this allocation, they were also randomly allocated to two forms of psychosocial support: 
case management conducted along motivational interviewing lines and intended to 
flexibly coordinate an individualised care package from various services; or a more 
standard and directly delivered series of individual counselling and group therapy 
sessions. Which of these support programmes a patient was allocated to made no 
difference to the main outcomes, so reports have focused on the pharmacotherapy 
options.
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Main findings
Over the next year 67% of the heroin patients remained in treatment but just 40% 
offered only methadone, a difference largely due to the 29% offered methadone who did 
not even start the treatment. Heroin enabled more patients than methadone (69% v. 
55%) to substantially curb illicit heroin use without countervailing increases in cocaine 
use, and more heroin patients experienced improved health. If both together were 
considered the criterion for success, this was achieved by 57% on heroin but only 45% 
on methadone. However, many methadone patients also substantially cut their heroin 
use and experienced improved health despite previous treatment having left them still 
dependent on heroin.
The main report on the trial records that the heroin option was not significantly more or 
less advantageous for patients recruited from methadone programmes versus those not 
in treatment at all for at least the past six months. The featured report took this analysis 
a step further by identifying who among the 'not in treatment patients' patients had 
never been in methadone maintenance treatment. How they responded to the offer of 
heroin could then be compared against the rest of the sample who had previously 
experienced methadone.
Around half the no-prior methadone patients stayed in treatment for the full 12 months 
of the follow-up regardless of whether they had been allocated to heroin or methadone. 
In terms of substantially curbing their heroin use without countervailing increases in 
cocaine use (  chart), patients with no previous experience of methadone maintenance 
were slightly more likely to do better if offered heroin as those previously on methadone, 
and on heroin they also committed crimes less frequently. Towards the end of the one-
year follow-up, they also experienced non-significantly better health if prescribed heroin, 
and used cocaine less frequently. But it was also the case that – for the first time – trying 
methadone in the context of the trial also had a substantial if lesser impact on all these 
outcomes.
The authors' conclusions
The featured study was the first to analyse the effects of heroin prescribing treatment in 
patients with no previous experience of opiate substitute prescribing programmes. Its 
findings show that such patients benefit from both heroin prescribing and methadone 
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maintenance to almost the same degree as patients previously in methadone 
maintenance treatment. Despite having no personal negative experiences with 
methadone, these patients also respond better to heroin prescribing than to methadone 
in terms of reduced illicit drug use and illegal activity, generally considered the two main 
goals of maintenance treatment. These differences could not be explained by greater 
retention on heroin, since retention was roughly the same on methadone. Possibly the 
prospect of either being allocated to heroin or, if not, switching to this option after a 
year, attracted patients in to maintenance therapy which they had previously avoided, 
and helped retain them even when they had been allocated to methadone. If this was the 
case, the possibility of heroin prescribing played a valuable role in encouraging treatment 
entry, and actually being prescribed heroin benefited more patients than oral methadone 
only.
These results call in to question whether heroin prescribing should only be implemented 
only as a second line treatment following the failure of methadone programmes, or 
whether it should be made available to all chronic, severely opioid-dependent patients, 
regardless of their previous experience with methadone treatment. 
 No studies have directly assessed how wide is the caseload who could 
benefit from heroin substantially more than from the best feasible oral methadone 
regimen. Only Britain in the 60s and 70s has experience of heroin prescribing as a truly 
front line specialist treatment for heroin addiction, deployed to attract addicts in to the 
newly established drug dependence clinics. In these special circumstances it fulfilled that 
role, but doctors rapidly moved patients on to the new oral methadone option pioneered 
in the USA, an attempt to engineer a more therapeutic and normalising regimen which 
made drug use, the effects of drugs, and particularly injecting, less central to patients' 
lives.
In those days supervised consumption was a rarity. Today with national authorities 
insisting on or encouraging supervision, heroin prescribing is less of an incentive to enter 
treatment because it entails twice-daily clinic attendance – a substantial disincentive, and 
one reason why trials have found it very difficult to recruit patients. On the other hand, 
one of the main reasons for insisting on supervised consumption – to avoid heroin being 
diverted on to the illicit market – is less salient because illicit heroin is so widely available 
that a little spillage from clinics could make little difference to the size of the addiction 
problem. Nevertheless, other reasons for supervising consumption and the need for 
clinics to sustain public and political support seem likely to continue to mandate 
supervision, at least initially.
A key question about heroin prescribing – whether it should be reserved to patients who 
have repeatedly done poorly on methadone, or used to attract patients suffering badly 
from their addiction but who will not engage with methadone – cannot be decided on the 
basis of the available research in to its effectiveness, partly because this aspect has not 
been adequately researched, and partly because many other important considerations 
influence that decision. Some of the issues are explored further below; in the current 
climate, the decisive factor seems likely to be cost rather than cost-effectiveness.
Only for methadone's failures?
Across all studies to date, a synthesis of findings published in 2010 found that prescribing heroin as opposed to 
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oral methadone to patients who have generally not done well in methadone programmes promotes retention, 
reduces the risk of relapse to illicit heroin use, and reduces crime – consequences (which also extend to 
improved health and social situations) partly due to longer retention, and partly to the greater impact of heroin 
prescribing even among patients still in treatment. The analysts' conclusion was that heroin prescription should 
remain a treatment of last resort for people failed by conventional maintenance treatment. Similar conclusions 
are found in UK national clinical guidelines and in guidance issued by England's National Treatment Agency for 
Substance Misuse. In particular, the latter is clear that injectable prescribing should be considered only for the 
minority of patients with persistently poor outcomes despite optimised oral programmes, and that the priority 
should be improving the effectiveness of oral maintenance treatment for the majority.
Relatively high cost, the risk of perpetuating injecting, the heavy responsibility placed on staff to safeguard lives 
during the injections they supervise, and the burden on patients required to attend the clinic to take their 
heroin, are among the reasons why heroin prescribing is seen as a niche last resort for methadone's failures. 
But this also means patients are forced to suffer life-threatening failures in methadone programmes before 
being offered heroin, and that others who could have benefited from heroin will not be offered it because they 
are so averse to methadone that they have never engaged with that treatment. It is this dilemma which the 
featured study addresses, finding evidence which calls in to question the need to insist on prior failed 
methadone tretments.
However, even in this study heroin prescribing was very far from a front line treatment. It was implemented 
only after prior treatments had failed to create or sustain recovery from heroin addiction, for patients who 
injected their drugs, had been dependent on opiate-type drugs for at least five years and regularly using heroin 
for on average over ten, and who generally also used other drugs, including cocaine and benzodiazepines. This 
background had left them all with poor mental and/or physical health (a requirement for joining the study) and 
generally they were in a very poor state on both fronts, including eight in 10 infected with hepatitis C. In other 
words, even in this study heroin prescribing was a second line treatment implemented well in to the addiction 
careers of patients who had shown themselves willing to continue to inject heroin nearly every day despite very 
serious ill health and prior attempts to stop.
Though the study was not set up to test the impact of prior failed methadone treatment, random allocation 
should have meant that differences between patients could not account for any extra benefit of prescribing 
heroin compared to methadone. Confirming this expectation, on all but one of 22 variables assessed by the 
study, the no-prior methadone patients allocated to heroin did not significantly differ from those offered only 
methadone.
The most recent British trial was confined to people continuing to inject illicit heroin despite being in methadone 
treatment, but it too offered some evidence that heroin can attract and retain patients who would not engage 
with oral methadone. The questions posed by the study were whether patients who remained wedded to illegal 
heroin despite extensive treatment were simply beyond available treatments, whether they needed injectable 
medications, or whether it was just that their current oral treatments were sub-optimal. For some, each of 
these three propositions was true. A third did seem beyond current treatments even as extended and optimised 
by the study. For a fifth, 'all' it took was to individualise and optimise dosing, psychosocial support and 
treatment planning in a continuing oral methadone programme. But despite these attempts to make the most 
of oral methadone, nearly half the patients only did well if prescribed injectable medications. A subsidiary 
finding was the unacceptability of oral methadone to many patients who did not start the treatment or who did 
but attended poorly, a sign perhaps that addicts who reject methadone maintenance, as well as those who try it 
but do not do well, may benefit from being prescribed heroin. Since missed urine tests were counted as 
positive, the unacceptability of methadone may have accounted for much of the greater reduction in illicit heroin 
use when the drug was legally prescribed. 
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